Loading organizations...
§ Private Profile · Bukit Merah, Central Region, Singapore
Design and manufacturing organization specializing in genetic medicines for biopharmaceutical companies, using synthetic biology.
GDMC is a Singapore-based design and manufacturing organization specializing in genetic medicines, including mRNA, plasmid DNA, and lentiviral vectors for advanced cell, gene, and nucleic acid therapies. The company utilizes synthetic biology to improve development processes and operates a Partnership for Drug Manufacturing Organisation model that supports biopharmaceutical clients from initial drug design through commercial manufacturing and regulatory approval. To scale its specialized contract manufacturing services, the firm successfully secured $21 million in Series A funding and initiated the phased construction of a 155,000-square-foot production facility. This financing round was led by Celadon Partners, with additional equity participation from WI Harper Group, SEEDS Capital, and NSG Ventures. Despite these significant infrastructure expansion efforts and early capital raises, the organization recently entered into voluntary liquidation. GDMC was founded in 2021 by Michael Koeris and Eric Blair.
GDMC has raised $21.0M across 1 funding round.
GDMC has raised $21.0M in total across 1 funding round.
GDMC has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 26, 2024 | $21M Series A | Celadon Partners | NSG Ventures, Seeds Capital, WI Harper Group | Announced |
GDMC has raised $21.0M in total across 1 funding round.
GDMC's investors include Celadon Partners, NSG Ventures, SEEDS Capital, WI Harper Group.